| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,260,000 |
| Market
Cap: |
11.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5036 - $0.5036 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PDS Biotechnology is a clinical-stage immunotherapy company developing a pipeline of molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co. owns the proprietary T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, for treatments in oncology and Infectimune™, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Co. is developing targeted product candidates to treat cancers including Human Papillomavirus associated cancers, melanoma, colorectal, lung, breast and prostate cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Loughlin James J |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
26,625 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
82,999 |
82,999 |
|
- |
|
| Blech Isaac |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Ratcliffe Liam |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
169,032 |
239,268 |
|
- |
|
| Barer Sol J |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
20,000 |
678,075 |
|
- |
|
| Spiegel Robert J. |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
48,661 |
|
- |
|
| Middlekauff W Bradford |
Senior VP, GC and Secretary |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
49,766 |
59,766 |
|
- |
|
| Conti Kurt G |
Director |
• • – |
2018-03-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(58,476) |
0 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-03-22 |
4 |
AS |
$16.41 |
$41,025 |
D/D |
(2,500) |
570,602 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-03-21 |
4 |
AS |
$16.52 |
$41,300 |
D/D |
(2,500) |
573,102 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-03-20 |
4 |
AS |
$16.47 |
$82,350 |
D/D |
(5,000) |
575,602 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-03-19 |
4 |
AS |
$16.66 |
$41,650 |
D/D |
(2,500) |
580,602 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-03-02 |
4 |
AS |
$15.08 |
$37,700 |
D/D |
(2,500) |
70,236 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-03-01 |
4 |
AS |
$14.81 |
$37,025 |
D/D |
(2,500) |
72,736 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-02-23 |
4 |
AS |
$15.37 |
$38,425 |
D/D |
(2,500) |
75,236 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-02-22 |
4 |
AS |
$15.47 |
$38,675 |
D/D |
(2,500) |
77,736 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-02-22 |
4 |
AS |
$14.49 |
$36,225 |
D/D |
(2,500) |
583,102 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-02-21 |
4 |
AS |
$13.82 |
$69,100 |
D/D |
(5,000) |
585,602 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2018-02-20 |
4 |
AS |
$13.75 |
$68,750 |
D/D |
(5,000) |
590,602 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-02-02 |
4 |
AS |
$12.96 |
$32,400 |
D/D |
(2,500) |
80,236 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-02-01 |
4 |
AS |
$13.14 |
$32,850 |
D/D |
(2,500) |
82,736 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-01-03 |
4 |
AS |
$10.11 |
$25,275 |
D/D |
(2,500) |
85,236 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2018-01-02 |
4 |
AS |
$10.11 |
$25,275 |
D/D |
(2,500) |
87,736 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2017-12-05 |
4 |
AS |
$9.68 |
$24,200 |
D/D |
(2,500) |
90,236 |
|
- |
|
122 Records found
|
|
Page 2 of 5 |
|
|
